The Clinical Impact of 21-Gene Recurrence Score on Treatment Decisions for Patients with Hormone Receptor-Positive Early Breast Cancer in Korea

키워드

참고문헌 (25)

1. 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival and Prevalence in 2010", Cancer Research and Treatment, 45(1), pp.1~14 (2013), 대한암학회[DOI]
2. Paik S, "Gene expression and benefit of chemotherapy in women with nodenegative, estrogen receptor-positive breast cancer", J Clin Oncol, 24, pp.3726~3734 (2006)
3. Paik S, "A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer", N Engl J Med, 351, pp.2817~2826 (2004)
4. Harris L, "American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer", J Clin Oncol, 25, pp.5287~5312 (2007)
5. "National Comprehensive Cancer Network Practice Guidelines in Oncology. Breast Cancer (version v3, 2013)" (2013)[URL]
6. Aebi S, "Primary breastcancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up", Ann Oncol, 22(Suppl 6), pp.12~24 (2011)
7. Goldhirsch A, "Strategies for subtypes: dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011", Ann Oncol, 22, pp.1736~1747 (2011)
8. Lo SS, "Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection", J Clin Oncol, 28, pp.1671~1676 (2010)
9. Geffen DB, "The impact of the 21-gene recurrence score assay on decision making about adjuvant chemotherapy in early-stage estrogen-receptor-positive breast cancer in an oncology practice with a unified treatment policy", Ann Oncol, 22, pp.2381~2386 (2011)
10. Albanell J, "Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive(ER+)nodenegative breast cancer", Ann Oncol, 23, pp.625~631 (2012)
11. Ademuyiwa FO, "The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort", Breast Cancer Res Treat, 126, pp.797~802 (2011)
12. Kamal AH, "Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score", Oncologist, 16, pp.1359~1366 (2011)
13. Asad J, "Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?", Am J Surg, 196, pp.527~529 (2008)
14. Eiermann W, "The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, nodenegative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use", Ann Oncol, 24, pp.618~624 (2013)
15. Joh JE, "The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists", Oncologist, 16, pp.1520~1526 (2011)
16. Hornberger J, "Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer", Am J Manag Care, 11, pp.313~324 (2005)
17. de Boer RH, "The impact of a genomic assay(Oncotype DX)on adjuvant treatment recommendations in early breast cancer", Med J Aust, 199, pp.205~208 (2013)
18. Biroschak JR, "Impact of Oncotype DX on treatment decisions in ER-positive, node-negative breast cancer with histologic correlation", Breast J, 19, pp.269~275 (2013)
19. Tsoi DT, "Costeffectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer", Oncologist, 15, pp.457~465 (2010)
20. Flanagan MB, "Histopathologic variables predict Oncotype DX recurrence score", Mod Pathol, 21, pp.1255~1261 (2008)
21. Wolf I, "Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients : a population-based study", Cancer, 112, pp.731~736 (2008)
22. Auerbach J, "Can features evaluated in the routine pathologic assessment of lymph node-negative estrogen receptor-positive stage I or II invasive breast cancer be used to predict the Oncotype DX recurrence score?", Arch Pathol Lab Med, 134, pp.1697~1701 (2010)
23. Geradts J, "The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features", Cancer Invest, 28, pp.969~977 (2010)
24. Goldstein LJ, "Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features", J Clin Oncol, 26, pp.4063~4071 (2008)
25. Sparano JA, "TAILORx : trial assigning individualized options for treatment(Rx)", Clin Breast Cancer, 7, pp.347~350 (2006)

관련 논문AI추천